ERBB2 and breast cancer: A study carried out in 2000 showed that a salivary proteomics-based panel of biomarkers, consisting of ERBB2/HER2, cancer antigen 15-3 (CA15-3), and tumor suppressor oncogene protein 53 (TP53/p53), has a potential use in the initial detection and follow-up screening for the detection of BC in women based on ELISA detection [222].